Close
Clinical Trial
Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease
The purpose of this study is to identify genetic variants that predict progression of prostate cancer.
Search result for "Solr search content"
Search Result for ""
Story
Game-changing prostate cancer treatment available at UT Health San Antonio
One in eight men will develop prostate cancer in their lifetime. Of those, one in 44 men will die of the disease. Those statistics from the American Cancer Society are startling. But men facing an advanced prostate cancer diagnosis who are seeking additional treatment options now have one more arrow in their quiver to […]
Story
Yoga improves quality of life in men with new diagnosis of prostate cancer
Yoga improved physical and mental well-being and promoted a robust immune response in a randomized clinical trial of men with prostate cancer.
Story
Clinical trial tackles the question of how much treatment is enough for prostate cancer
According to the National Cancer Institute, more than 3 million men are living with prostate cancer in the United States. Of those, survivorship after five years is 97 percent. With patients living longer and physicians seeing younger patients with this type of cancer, learning the best ways to treat patients and providing a better […]
Story
Mays Cancer Center’s latest radiation therapy reduces treatment times, increases favorable outcomes for prostate cancer
Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, introduces the newest technology in treating prostate cancer. This innovative method is called stereotactic body radiation therapy (SBRT), a minimally invasive therapy using high amounts of radiation with millimeter precision to destroy tumors in the prostate. Stereotactic body radiation therapy is a […]
Story
UT Health San Antonio study shows MRI technique improves detection of aggressive prostate cancer
An MRI scan called restriction spectrum imaging greatly improves the detection of prostate cancer progression, according to a published study by researchers at The University of Texas Health Science Center at San Antonio, also known as UT Health San Antonio.
Clinical Trial
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer
This is a Phase 1a, first-in-human, open-label dose-escalation study to determine the RDR and/or MTD, and to assess the DLT of INV-9956. The safety, tolerability, PK/PD, and preliminary antitumor activity of INV-9956 will be assessed in adult patients with advanced mCRPC.
Clinical Trial
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of lutetium (177Lu) vipivotide tetraxetan (AAA617) alone and lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.
Story
Exploring technological advances in patient treatment
Mays Cancer Center is at the forefront of technology-assisted surgical treatments that are improving patient recovery.
Story
The biology of cancer
Mays Cancer Center researchers are making significant strides in understanding risk factors and conditions that cause cancers to develop and progress and assessing impacts on the health and recovery of patients with cancer.